Phase I/IIa Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Cerulean Pharma; NewLink Genetics Corporation
- 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
- 06 Oct 2016 According to a Cerulean Pharma media release, data from the study will be presented at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting.